This announcement is a separate document:
信達生物:自願公告 - 國家藥品監督管理局受理耐立克治療耐藥慢性髓細胞白血病上市申請並納入優先審評
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED AND GRANTED PRIORITY REVIEW DESIGNATION TO A NEW DRUG APPLICATION FOR OLVEREMBATINIB FOR THE TREATMENT OF DRUG-RESISTANT CHRONIC MYELOID LEUKEMIA
Jul 19, 2022 17:00
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.